Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies
Hematology Reports · 23.06.2026 · 18 (4) · 43
DOI: 10.3390/hematolrep18040043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 23.06.2026. Verfasst von Jerry Qi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Lisocabtagene maraleucel (liso-cel) is a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). However, most published meta-analyses of CAR-T therapy in LBCL pool data across products, limiting product-specific interpretation.
Methods
We conducted a systematic review and meta-analysis of clinical trials and retrospective real-world studies evaluating liso-cel monotherapy in R/R LBCL. The primary endpoint was the overall response rate (ORR). Secondary endpoints included complete response (CR), incidence of grade ≥ 3 adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), overall mortality rate (OMR), disease progression-related mortality, and adverse event-related mortality. Pooled proportions were estimated using random-effects models.
Results
Eleven studies including 1206 patients were analyzed, comprising five clinical trials and six real-world retrospective cohorts. The pooled ORR was 78%, and the pooled CR rate was 60%. The pooled OMR was 38%, with a disease progression-related mortality of 28% and an adverse event-related mortality of 4%. Severe (grade ≥ 3) CRS and ICANS occurred in 2% and 8%, respectively. Severe (grade ≥ 3) hematologic toxicities were frequent, particularly neutropenia, thrombocytopenia, and anemia.
Conclusions
Liso-cel monotherapy demonstrated high pooled response rates and low pooled incidences of severe CRS and ICANS across clinical trials and real-world settings in R/R LBCL. Severe ICANS, although uncommon, remains clinically meaningful, and severe hematologic toxicities were frequent and warrant careful monitoring and supportive care. These findings provide product-specific benchmarks for liso-cel in R/R LBCL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA.
- Department of Medicine, University of California, San Francisco, Fresno Campus, 155 N. Fresno Street, Fresno, CA 93701, USA.
- School of Medicine, University of California, Riverside, 900 University Ave., Riverside, CA 92521, USA.
- College of Medicine, University of Central Florida, 6850 Lake Nona Blvd., Orlando, FL 32827, USA.
- Division of Transplant, Cellular Therapy, and Hematological Malignancies, Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA.
ORCID-Profile: Jerry Qi, Austin Yang, Kareem Latif, Sarkis Dagley
Zitieren
APA
Qi, J., Park, D., Kejriwal, N., Yang, A., Latif, K., Dagley, S., & Akhtari, M. (2026). Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies. Hematology Reports, 18(4), 43. https://doi.org/10.3390/hematolrep18040043
Vancouver
Qi J, Park D, Kejriwal N, Yang A, Latif K, Dagley S, et al. Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies. Hematology Reports. 2026;18(4):43. doi:10.3390/hematolrep18040043
BibTeX
@article{Qi2026,
author = {Qi, Jerry and Park, Daniel and Kejriwal, Nidhi and Yang, Austin and Latif, Kareem and Dagley, Sarkis and Akhtari, Mojtaba},
title = {Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {4},
pages = {43},
doi = {10.3390/hematolrep18040043}
}
EUVIMED